Endorsed in 2011, Xarelto (rivaroxaban) is one of the most popular blood thinners available and is fabricated by Bayer and showcased in the U.S. by Johnson and Johnson's auxiliary, Janssen Pharmaceuticals. Xarelto is gotten over $2 billion for J&J in 2016 alone, as indicated by the organization's yearly report. Be that as it may, individuals harmed by the medication say its producers put benefit before security. The most perilous reaction for individuals who take Xarelto is inside dying. The medication does not have a cure, and previous Xarelto clients documented lawsuits saying they were not adequately cautioned about the pharmaceutical's hazard. A few offended parties documented wrongful passing suits after friends and family kicked the bucket from Xarelto dying. Attorneys included in prosecution say Xarelto clinical trials have high rates of missing information, neglect to address the absence of a counteractant and neglect to give sufficient